We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Precision Medicine Institute
Colleague Insights
Video Expert Opinion
Resource Library
Conferences
Tumor Boards
Sign in
Join now
featured
Published in Lung Cancer

Expert Opinion / Cases · March 24, 2021

Stage IIIB Lung Adenocarcinoma With EGFR L858R Mutation

Written by
Michael J. Grant MD

 

 Save  Recommend
 Share

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • paola antonelli

    Mar 27, 2021

    ICI in EGFR mutant NSCLC are not recomended. If possibile I'd choose an EGFR TKI, like Osimertinib (as in adjuvant setting)

  • Jean-Yves Douillard

    Apr 06, 2021

    Standard of care for locally advanced unresectable NSCLC has recently changed with the addition of Durvalumab post treatment with concurrent chemoradiation. In the present case above, the patient however has an L858R EGFR mutation. In the Pacific trials, these patients were eligible but represent only 34/709 patients in total. According to the latest updated (early 2021) Forest plot, EGFR mutated patient do not be benefit from consolidation with Durvalumab on OS (HR 0.97; 0.40-2.33), and cannot be recommended
The use of adjuvant Osimertinib as consolidation in the setting of Stage IIIB post chemoradiation is less documented. Trials evaluating Osimertinib post resection have shown a benefit in DFS but there is no proof of an OS benefit. 
The risk/benefit of consolidation has not been evaluated. Toxicity and Quality of life have to be considered in patients potentially cured after chemoradiation. 
Prognostic biomarkers are needed to potentially help treatment decision, in that instance circulating tumour DNA (ctDNA) could be used and if ctDNA is detected, Osimertinib could be prescribed and its efficacy measured of repeated ctDNA testing.
If not, I would personally opt for an imaging surveillance or look for a clinical trial addressing the question.

  • GALA NAUSICAA  ROMERO MORATALLA

    Nov 18, 2021

    EGFR L858R mutation was positive 
Now I think she must treament with TKI inhibitor (Osimertinib) before anti PD- 1 treatment by Guidelines

  • GALA NAUSICAA  ROMERO MORATALLA

    Nov 18, 2021

    EGFR L858R mutation was positive 
Now I think she must treament with TKI inhibitor (Osimertinib) before anti PD- 1 treatment by Guidelines

  • Jul 06, 2022

    Pending Moderator approval.
    Delete

Further Reading

Most Read This Week

Recently Updated